Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (37)	11/1/2000 10:12:36 AM
From: scaram(o)uche	Read Replies (3) \| Respond to of 1784

Some here know my background. For a couple of years, I was V.P. Product Development at a competitor right down the road from them. We kicked their butts, pretty badly and very visibly. However, they were the reagents company to move through the funding window when it opened. My gut feeling is that digesting LTEK will make further consolidation risky. If they can integrate companies efficiently, then I'll give them a respectful bow after the fact. Projecting forward (diluted), that's $1.04/share. Not bad, but I don't understand the impact of the add back of non-cash amortization. Shareholder equity is only $200M.... we can't forget that these guys/gals are operating largely on the basis of borrowed money. Big war chest. Amazing execution. I'd love to see someone write a book about this one.

To: Biomaven who wrote (37)	11/1/2000 12:56:25 PM
From: tuck	Read Replies (2) \| Respond to of 1784

Peter, I've just started looking at ILXO. They just announced results today: siliconinvestor.com I was surprised to find this sentence: "Total revenue for the quarter increased 48% to $7.4 million, compared with $5.0 million in the third quarter of 1999. This includes $6.6 million in revenue from the company's CRO business, up 69% from $3.9 million in the same period a year ago." Do any of you folks follow this company closely? Is their CRO business considered a key part of the business plan? I didn't see earnings attributed to the CRO biz, but in the absence of milestone payments, it sure seems to make up most of the revenue. Could this be considered a trickle company? Looks like it's headed for a breakout: siliconinvestor.com Wondering if the Trickle Portfolio should do some rapid DD on ILXO if it's considered within jurisdiction. Cheers, Tuck